FOX Translator
No data currently available.
No data currently available.
TITLE
Many people know that the Federal Reserve sets interest rates in order to loan money to other banks so they can keep cash flowing throughout the U.S. financial system. Mostly, this works great for everyone involved. But, sometimes, banks and thrifts need a little extra cash, mostly so they can meet the reserve requirement (the minimum amount of deposits banks need to be considered in good financial shape).
To meet the reserve, the Fed has what's known as the discount window, which allows banks to borrow money for a short period of time at a higher interest rate (called the discount rate) than the official Federal Funds rate.
It's called a window because it used to be an actual teller window, where banks would go to borrow from the federal government. Now, it's used more as a lender of last resort. In fact, banks prefer to borrow from one another than directly from the discount window, since the interest owed can be cheaper and going to the discount window tends to imply that the bank is in a spot of trouble.
The Fed, too, doesn't like banks borrowing this way, which is why the discount rate is always higher than the target rate. It also requires banks to collateralize the loans, meaning they have to turn over liquid assets, such as loans or CDs, to the Fed in order to get the money. As with any loan, the banks get the underlying collateral back when they pay off the balance.
Home / Markets / Industries / Health Care
Thursday, March 27, 2008
FDA Investigating Safety Of Merck's Singulair
Val Brickates Kennedy
MarketWatch Pulse
BOSTON -- According to its website, the Food and Drug Administration is investigating reports that Merck & Co.'s popular asthma drug Singulair may have triggered ususual mood swings and even suicidal behavior in some users. The drug is used to treat asthma and respiratory allergies. Singulair's labeling already notes that use might trigger depression, tremors, suicidal thinking and anxiousness in certain patients. The agency said it has asked Merck to further evaluate existing clinical data on Singulair for signs of suicidality. The FDA likewise plans to review reports it has received on the issue, which could take up to 9 months. The FDA recommends that patients should not stop taking Singulair until they have discussed their concerns with thier doctor.
Copyright © 2008 MarketWatch, Inc.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |



